人类肝脂肪变性的遗传决定因素。
Genetic determinants of hepatic steatosis in man.
机构信息
Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth, Australia.
出版信息
J Lipid Res. 2011 Apr;52(4):593-617. doi: 10.1194/jlr.R008896. Epub 2011 Jan 18.
Abstract
Hepatic steatosis is one of the most common liver disorders in the general population. The main cause of hepatic steatosis is nonalcoholic fatty liver disease (NAFLD), representing the hepatic component of the metabolic syndrome, which is characterized by type 2 diabetes, obesity, and dyslipidemia. Insulin resistance and excess adiposity are considered to play key roles in the pathogenesis of NAFLD. Although the risk factors for NAFLD are well established, the genetic basis of hepatic steatosis is largely unknown. Here we review recent progress on genomic variants and their association with hepatic steatosis and discuss the potential impact of these genetic studies on clinical practice. Identifying the genetic determinants of hepatic steatosis will lead to a better understanding of the pathogenesis and progression of NAFLD.
摘要
肝脂肪变性是普通人群中最常见的肝脏疾病之一。肝脂肪变性的主要病因是非酒精性脂肪性肝病（NAFLD），它是代谢综合征的肝脏组分，其特征为 2 型糖尿病、肥胖和血脂异常。胰岛素抵抗和过多的脂肪组织被认为在 NAFLD 的发病机制中发挥关键作用。尽管 NAFLD 的危险因素已得到很好的确立，但肝脂肪变性的遗传基础在很大程度上仍是未知的。本文综述了与肝脂肪变性相关的基因组变异及其相关性的最新进展，并讨论了这些遗传研究对临床实践的潜在影响。确定肝脂肪变性的遗传决定因素将有助于更好地理解 NAFLD 的发病机制和进展。
相似文献
1
Genetic determinants of hepatic steatosis in man.人类肝脂肪变性的遗传决定因素。
J Lipid Res. 2011 Apr;52(4):593-617. doi: 10.1194/jlr.R008896. Epub 2011 Jan 18.
2
Genetics of alcoholic and nonalcoholic fatty liver disease.酒精性和非酒精性脂肪性肝病的遗传学。
Semin Liver Dis. 2011 May;31(2):128-46. doi: 10.1055/s-0031-1276643. Epub 2011 May 2.
3
Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis.非酒精性脂肪性肝病和脂肪性肝炎发病机制中的遗传因素
Biomed Res Int. 2015;2015:460190. doi: 10.1155/2015/460190. Epub 2015 Jul 27.
4
Multi-SNP analysis of GWAS data identifies pathways associated with nonalcoholic fatty liver disease.多单核苷酸多态性分析全基因组关联研究数据确定与非酒精性脂肪性肝病相关的途径。
PLoS One. 2013 Jul 19;8(7):e65982. doi: 10.1371/journal.pone.0065982. Print 2013.
5
Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in mice.氧化应激和饮食诱导肥胖炎症反应中的基因差异不会改变小鼠的肝纤维化。
Liver Int. 2009 Sep;29(8):1262-72. doi: 10.1111/j.1478-3231.2009.02036.x. Epub 2009 Apr 20.
6
Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study.肝脂肪变性与肝纤维化之间的共同遗传效应：一项前瞻性双生子研究。
Hepatology. 2016 Nov;64(5):1547-1558. doi: 10.1002/hep.28674. Epub 2016 Jul 25.
7
Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.分子机制：非酒精性脂肪性肝病、脂肪性肝炎和肝细胞癌之间的联系。
Int J Mol Sci. 2020 Feb 23;21(4):1525. doi: 10.3390/ijms21041525.
8
Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.血小板反应蛋白 1 可改善饮食诱导的胰岛素抵抗小鼠的肝脂肪变性，并且与人类的肝脂肪含量相关。
EBioMedicine. 2020 Jul;57:102849. doi: 10.1016/j.ebiom.2020.102849. Epub 2020 Jun 21.
9
Obesity and fatty liver are 'grease' for the machinery of hepatic fibrosis.肥胖和脂肪肝是肝纤维化机制的“润滑剂”。
Dig Dis. 2011;29(4):377-83. doi: 10.1159/000329800. Epub 2011 Aug 30.
10
The role of the lipogenic pathway in the development of hepatic steatosis.脂肪生成途径在肝脂肪变性发展中的作用。
Diabetes Metab. 2008 Dec;34(6 Pt 2):643-8. doi: 10.1016/S1262-3636(08)74599-3.
引用本文的文献
1
Insulin resistance in type 2 diabetes mellitus.2型糖尿病中的胰岛素抵抗。
Nat Rev Endocrinol. 2025 Apr 17. doi: 10.1038/s41574-025-01114-y.
2
Autoimmune mechanisms and inflammation in obesity-associated type 2 diabetes, atherosclerosis, and non-alcoholic fatty liver disease.肥胖相关的2型糖尿病、动脉粥样硬化和非酒精性脂肪性肝病中的自身免疫机制与炎症
Funct Integr Genomics. 2025 Apr 9;25(1):84. doi: 10.1007/s10142-025-01587-0.
3
Healthy Lifestyle Changes Improve Cortisol Levels and Liver Steatosis in MASLD Patients: Results from a Randomized Clinical Trial.健康的生活方式改变可改善代谢功能障碍相关脂肪性肝病（MASLD）患者的皮质醇水平和肝脂肪变性：一项随机临床试验的结果
Nutrients. 2024 Dec 6;16(23):4225. doi: 10.3390/nu16234225.
4
()-5-hydroxy-7-methoxy-3-(2-hydroxybenzyl)-4-chromanone, a Major Homoisoflavonoid, Attenuates Free Fatty Acid-Induced Hepatic Steatosis by Activating AMPK and PPARα Pathways in HepG2 Cells.()-5-羟基-7-甲氧基-3-(2-羟基苄基)-4-色原酮，一种主要的异黄酮类化合物，通过激活 HepG2 细胞中的 AMPK 和 PPARα 通路来减轻游离脂肪酸诱导的肝脂肪变性。
Nutrients. 2024 Oct 14;16(20):3475. doi: 10.3390/nu16203475.
5
Computational Strategies for Assessing Adverse Outcome Pathways: Hepatic Steatosis as a Case Study.计算策略评估不良结局途径：以肝脂肪变性为例。
Int J Mol Sci. 2024 Oct 17;25(20):11154. doi: 10.3390/ijms252011154.
6
Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia.洛美他派在家族性高胆固醇血症纯合子患者中的长期肝脏安全性。
Liver Int. 2023 Feb;43(2):413-423. doi: 10.1111/liv.15497. Epub 2022 Dec 30.
7
Liver Fat Assessment with Body Shape.体形成像评估肝脏脂肪。
Annu Int Conf IEEE Eng Med Biol Soc. 2022 Jul;2022:2716-2719. doi: 10.1109/EMBC48229.2022.9871321.
8
Intramuscular Fat Selection in Rabbits Modifies the Fatty Acid Composition of Muscle and Liver Tissues.兔肌肉内脂肪的选择改变了肌肉和肝脏组织的脂肪酸组成。
Animals (Basel). 2022 Mar 31;12(7):893. doi: 10.3390/ani12070893.
9
Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease.遗传多态性对非酒精性脂肪性肝病治疗反应的影响。
Nutrients. 2021 Nov 15;13(11):4077. doi: 10.3390/nu13114077.
10
Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico.血清脂质与非酒精性脂肪性肝病有关：墨西哥的一项初步病例对照研究。
Lipids Health Dis. 2021 Oct 10;20(1):136. doi: 10.1186/s12944-021-01526-5.
本文引用的文献
1
Specifically PNPLA3-mediated accumulation of liver fat in obese patients with type 2 diabetes.具体来说，PNPLA3 介导的肥胖 2 型糖尿病患者肝脏脂肪堆积。
J Clin Endocrinol Metab. 2010 Dec;95(12):E430-6. doi: 10.1210/jc.2010-0814. Epub 2010 Sep 8.
2
A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents.载脂蛋白 L3 基因（PNPLA3）中的常见变异与肥胖儿童和青少年的脂肪肝疾病有关。
Hepatology. 2010 Oct;52(4):1281-90. doi: 10.1002/hep.23832.
3
CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance.CGI-58 基因敲低的小鼠发生肝脂肪变性，但可预防饮食诱导的肥胖和葡萄糖不耐受。
J Lipid Res. 2010 Nov;51(11):3306-15. doi: 10.1194/jlr.M010256. Epub 2010 Aug 27.
4
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease.载脂蛋白样磷脂酶域蛋白 3（PNPLA3）基因多态性与非酒精性脂肪性肝病组织学严重程度的关系。
Hepatology. 2010 Sep;52(3):894-903. doi: 10.1002/hep.23759.
5
Pioglitazone in the treatment of NASH: the role of adiponectin.吡格列酮治疗非酒精性脂肪性肝炎：脂联素的作用。
Aliment Pharmacol Ther. 2010 Sep;32(6):769-75. doi: 10.1111/j.1365-2036.2010.04405.x.
6
Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease.在小鼠中缺乏 patatin 样磷酸脂酶结构域包含蛋白 3/脂联素与脂肪肝无关。
Hepatology. 2010 Sep;52(3):1134-42. doi: 10.1002/hep.23812.
7
I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease.I148M 伴血小板型磷酸脂酶结构域包含 3 基因变异与儿科非酒精性脂肪性肝病严重程度的关系。
Hepatology. 2010 Oct;52(4):1274-80. doi: 10.1002/hep.23823.
8
The effects of palmitate on hepatic insulin resistance are mediated by NADPH Oxidase 3-derived reactive oxygen species through JNK and p38MAPK pathways.软脂酸通过 NADPH 氧化酶 3 产生的活性氧自由基通过 JNK 和 p38MAPK 通路介导肝胰岛素抵抗。
J Biol Chem. 2010 Sep 24;285(39):29965-73. doi: 10.1074/jbc.M110.128694. Epub 2010 Jul 20.
9
Central players in inherited lipodystrophies.遗传性脂肪营养不良的核心参与者。
Trends Endocrinol Metab. 2010 Oct;21(10):581-8. doi: 10.1016/j.tem.2010.06.006. Epub 2010 Jul 10.
10
Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function.人肝肠型脂肪酶缺乏症中微粒体甘油三酯转移蛋白的原发性缺乏与 CD1 功能丧失有关。
J Clin Invest. 2010 Aug;120(8):2889-99. doi: 10.1172/JCI42703. Epub 2010 Jul 1.
Zotero 插件